CClinicalTrials.gg
RecruitingNCT06541340PROBUpdated Aug 7, 2024

A New Strategy for Preoperative Drainage of Resectable Pancreatic Head Cancer Combined Severe Obstructive Jaundice

An interventional study of Modified strategy and Traditional strategy in Pancreatic Cancer and Obstructive Jaundice, sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-07.

Sponsored by Ruijin Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
360
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Severe obstructive jaundice caused by pancreatic head cancer usually requires preoperative biliary drainage, but its necessity and effectiveness are controversial, and specific strategies lack clear standards. This study proposed a new strategy for preoperative biliary drainage using serum prealbumin as the main evaluation index, and compared it with the traditional strategy using serum total bilirubin as the main evaluation index. Through a randomized, controlled, multicenter prospective study, we explored the effects of different drainage strategies on the incidence of in-hospital complications and long-term prognosis of patients with resectable pancreatic head cancer, guided clinical decisions on preoperative drainage time and surgical timing, and provided high-quality evidence-based medicine for preoperative biliary drainage of pancreatic head cancer.

02

Conditions studied

  • Pancreatic Cancer
  • Obstructive Jaundice

Keywords

  • pancreatic head cancer
  • obstructive Jaundice
  • preoperative biliary drainage
  • prealbumin
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Pathological diagnosis of pancreatic head cancer, or clinical diagnosis of pancreatic head cancer after multidisciplinary discussion, clear presence of obstructive jaundice caused by pancreatic head tumor, and planned to undergo radical pancreaticoduodenectomy
  2. Preoperative imaging stage is resectable
  3. Baseline serum total bilirubin ≥ 250μmol/L, and no history of preoperative biliary drainage
  4. Age >18 and ≤75 years old
  5. ECOG(Eastern Cooperative Oncology Group) physical score ≤ 2
  6. Signed informed consent, received preoperative endoscopic biliary drainage (ERCP) and radical surgery timing evaluation

Exclusion criteria

Exclusion Criteria:

  1. Combined with other malignant tumors
  2. Combined with uncontrolled medical diseases or organ dysfunction and other absolute counterindications for surgery
  3. Pregnant and lactating women
  4. Patients who cannot tolerate preoperative biliary drainage or radical surgery
  5. Other situations that are not suitable for inclusion in clinical trials
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Active comparator
    Traditional strategy

    Traditional preoperative biliary drainage strategy with total bilirubin as the main indicator

    Procedure: Traditional strategy

  • Experimental
    Modified strategy

    Modified preoperative biliary drainage strategy with prealbumin as the main indicator

    Procedure: Modified strategy

Interventions

  • ProcedureModified strategy

    Modified preoperative biliary drainage strategy with prealbumin as the main indicator

  • ProcedureTraditional strategy

    Traditional preoperative biliary drainage strategy with total bilirubin as the main indicator

05

What researchers measure

Primary outcomes

  1. In-hospital complications

    In-hospital complications are comprehensively evaluated by the chief surgeon, responsible doctor and their team based on clinical manifestations, laboratory tests, etc., and reviewed by the expert committee of this study. The name of the complication, time of occurrence, treatment measures and outcome are strictly recorded.

    Time frame: During hospitalization, up tp 3 months

Secondary outcomes

  1. Recurrence/metastasis

    It is mainly based on follow-up. If the follow-up was completed in our hospital, the hospital system will be directly retrieved to obtain the diagnosis information. The follow-up was conducted by interviewing the patient or his family members through telephone questionnaires or face-to-face visits to collect required information.The follow-up subjects provide medical records, etc., and record in detail the time of diagnosis of long-term complications or recurrence and metastasis, diagnostic basis, laboratory tests, treatment measures and outcomes, which must be reviewed by the expert committee of this study.

    Time frame: 12 months after discharge

  2. Mortality

    It is mainly based on follow-up. If the follow-up was completed in our hospital, the hospital system will be directly retrieved to obtain the diagnosis information. The follow-up was conducted by interviewing the patient or his family members through telephone questionnaires or face-to-face visits to collect required information.The follow-up subjects provide medical records, etc., and record in detail the time of diagnosis of long-term complications or recurrence and metastasis, diagnostic basis, laboratory tests, treatment measures and outcomes, which must be reviewed by the expert committee of this study.

    Time frame: 12 months after discharge

  3. Long-term complications

    It is mainly based on follow-up. If the follow-up was completed in our hospital, the hospital system will be directly retrieved to obtain the diagnosis information. The follow-up was conducted by interviewing the patient or his family members through telephone questionnaires or face-to-face visits to collect required information.The follow-up subjects provide medical records, etc., and record in detail the time of diagnosis of long-term complications or recurrence and metastasis, diagnostic basis, laboratory tests, treatment measures and outcomes, which must be reviewed by the expert committee of this study.

    Time frame: 12 months after discharge

06

Study locations

1 of 1 sites recruiting
  • Ruijin Hospital Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai 200025, China
    • Baiyong Shen, Ph.D&M.D · Contact · 0086-021-64370045
    • Baiyong Shen, Ph.D&M.D · Principal investigator
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06541340
Lead sponsor
Ruijin Hospital
Responsible party
Sponsor
First posted
Aug 7, 2024
Start date
Aug 1, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 7, 2024

Study contacts

Jun Zhang, Ph.D&M.D
Contact
zj11477@rjh.com.cn
+86 18917530547

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion